251 related articles for article (PubMed ID: 6436037)
21. Turnover of specific [3H]spiperone and [3H]N,n-propylnorapomorphine binding sites in rat striatum following phenoxybenzamine administration.
Hall MD; Jenner P; Marsden CD
Biochem Pharmacol; 1983 Oct; 32(19):2973-7. PubMed ID: 6626267
[TBL] [Abstract][Full Text] [Related]
22. Chronic proglumide increases [3H]spiperone binding in the rat brain.
Bean AJ; Baldy WJ; Martin GE
Eur J Pharmacol; 1985 Oct; 117(1):97-101. PubMed ID: 4085545
[TBL] [Abstract][Full Text] [Related]
23. Analysis of [3H]spiperone binding sites in the rat striatum and frontoparietal cortex by means of quantitative receptor autoradiography after inactivation of dopamine receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vivo: selective protection by sulpiride in the striatum.
Fuxe K; Meller E; Goldstein M; Benfenati F; Agnati LF
Neurosci Lett; 1986 Feb; 64(2):163-8. PubMed ID: 3960398
[TBL] [Abstract][Full Text] [Related]
24. Effects of alloxan-induced diabetes on dopaminergic receptors in rat striatum and anterior pituitary.
Serri O; Renier G; Somma M
Horm Res; 1985; 21(2):95-101. PubMed ID: 3979949
[TBL] [Abstract][Full Text] [Related]
25. Denervation supersensitivity of striatal D2 dopamine receptors is restricted to the ventro- and dorsolateral regions of the striatum.
Savasta M; Dubois A; Feuerstein C; Manier M; Scatton B
Neurosci Lett; 1987 Feb; 74(2):180-6. PubMed ID: 2883609
[TBL] [Abstract][Full Text] [Related]
26. Ontogeny of dopaminergic function in the rat midbrain tegmentum, corpus striatum and frontal cortex.
Noisin EL; Thomas WE
Brain Res; 1988 Jun; 469(1-2):241-52. PubMed ID: 3401800
[TBL] [Abstract][Full Text] [Related]
27. Binding of 3H-spiperone and 3H-(-)-sulpiride to dopamine D2 receptors in rat striatal membranes: methodological considerations and demonstration of the identical nature of the binding sites for the two ligands.
Urwyler S; Coward D
Naunyn Schmiedebergs Arch Pharmacol; 1987 Feb; 335(2):115-22. PubMed ID: 2951601
[TBL] [Abstract][Full Text] [Related]
28. Kainate lesion dissociates striatal dopamine receptor radioligand binding sites.
Leff S; Adams L; Hyttel J; Creese I
Eur J Pharmacol; 1981 Mar; 70(1):71-5. PubMed ID: 7215442
[TBL] [Abstract][Full Text] [Related]
29. Apomorphine-induced rotation in the unilateral 6-OHDA-lesioned rat: relationship to changes in striatal adenylate cyclase activity and 3H-spiperone binding.
Waddington JL; Cross AJ; Longden A; Owen F; Poulter M
Neuropharmacology; 1979 Jul; 18(7):643-5. PubMed ID: 573871
[No Abstract] [Full Text] [Related]
30. Neonatal dopamine lesion in the rat results in enhanced adenylate cyclase activity without altering dopamine receptor binding or dopamine- and adenosine 3':5'-monophosphate-regulated phosphoprotein (DARPP-32) immunoreactivity.
Luthman J; Lindqvist E; Young D; Cowburn R
Exp Brain Res; 1990; 83(1):85-95. PubMed ID: 1981564
[TBL] [Abstract][Full Text] [Related]
31. Are striatal [3H]spiperone radioreceptor assays indicative of multiple dopamine receptor interactions?
Clements-Jewery S; Robson PA
Neuropharmacology; 1981 Dec; 20(12B):1295-8. PubMed ID: 7322304
[No Abstract] [Full Text] [Related]
32. Posture-independent sensorimotor analysis of inter-hemispheric receptor asymmetries in neostriatum.
Schallert T; Upchurch M; Wilcox RE; Vaughn DM
Pharmacol Biochem Behav; 1983 May; 18(5):753-9. PubMed ID: 6407036
[TBL] [Abstract][Full Text] [Related]
33. Functional distinction between DA-stimulated adenylate cyclase and 3H-spiperone binding sites in rat striatum.
Waddington JL; Cross AJ; Longden A; Owen F; Poulter M
Eur J Pharmacol; 1979 Oct; 58(3):341-2. PubMed ID: 510367
[No Abstract] [Full Text] [Related]
34. The effects of chronic bromocriptine treatment on behaviour and dopamine receptor binding in the rat striatum.
Traub M; Wagner HR; Hassan M; Jackson-Lewis V; Fahn S
Eur J Pharmacol; 1985 Nov; 118(1-2):147-54. PubMed ID: 3936723
[TBL] [Abstract][Full Text] [Related]
35. Chronic haloperidol affects striatal D2-dopamine receptor reappearance after irreversible receptor blockade.
Pich EM; Benfenati F; Farabegoli C; Fuxe K; Meller E; Aronsson M; Goldstein M; Agnati LF
Brain Res; 1987 Dec; 435(1-2):147-52. PubMed ID: 2962698
[TBL] [Abstract][Full Text] [Related]
36. Definition of the in-vivo accumulation of [3H]spiperone in brain using haloperidol and sulpiride to determine functional dopamine receptor occupation.
Chivers JK; Reavill C; Jenner P; Marsden CD
J Pharm Pharmacol; 1988 Sep; 40(9):613-9. PubMed ID: 2907027
[TBL] [Abstract][Full Text] [Related]
37. Comparison of dopamine receptor sites labeled by [3H]-S-sulpiride and [3H]-spiperone in striatum.
Zahniser NR; Dubocovich ML
J Pharmacol Exp Ther; 1983 Dec; 227(3):592-9. PubMed ID: 6655559
[TBL] [Abstract][Full Text] [Related]
38. The effects of REM sleep deprivation on striatal dopamine receptor sites.
Zwicker AP; Calil HM
Pharmacol Biochem Behav; 1986 Apr; 24(4):809-12. PubMed ID: 3012593
[TBL] [Abstract][Full Text] [Related]
39. Postsynaptic location of acrylamide-induced modulation of striatal 3H-spiroperidol binding.
Hong JS; Tilson HA; Agrawal AK; Karoum F; Bondy SC
Neurotoxicology; 1982 Jul; 3(1):108-12. PubMed ID: 6890181
[TBL] [Abstract][Full Text] [Related]
40. In vivo binding of spiperone and N-methylspiperone to dopaminergic and serotonergic sites in the rat brain: multiple modeling and implications for PET scanning.
Swart JA; van der Werf JF; Wiegman T; Paans AM; Vaalburg W; Korf J
J Cereb Blood Flow Metab; 1990 May; 10(3):297-306. PubMed ID: 1970341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
